

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gary D. Glick et al.

Serial No.:

09/700,101 11/08/2000 Group No.: Examiner:

not assigned not assigned

Filed: Entitled:

Therapeutic Applications Of Pro-Apoptotic

Benzodiazepines

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated September 1, 2005

Sir or Madam:

Enclosed please find a Supplemental Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

This Information Disclosure Statement is being filed before the issuance of a first Office Action, therefore Applicant believes no fee is required. If the Commissioner deems otherwise the Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: September 1, 2005

Registration No. 55,210

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 608/218-6900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gary D. Glick et al.

Serial No.:

09/700,101

Filed:

11/08/00

Group No.: not assigned

Examiner:

not assigned

Entitled:

Therapeutic Applications Of Pro-Apoptotic

Benzodiazepines

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in 1450, Alexandria, VA 22313-1450, on September an envelope addressed to the: Commissioner for Patents, 1, 2005.

Mary Ellen Waite

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- Beurdeley-Thomas et al., Journal of Neuro-Oncology 46 (2000) 45-56
- Churcher et al., Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-183
- Darrow et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132
- Herranz, Medicinal Research Reviews 23 (2003) 559-603
- Ramdas et al., Archieves of Biochemistry and Biophysics 368 (1999) 394-400
- Ursini et al., J. Med. Chem. 43 (2000) 3596-3613

This Information Disclosure Statement under 37 C.F.R. §§1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: September 1, 2005

Robert/A. Goetz
Registration No. 55,210
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
608/218-6900

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Requestion Act

Substitute for form 1449/PTO			EMIN	Complete if Known			
Substitut				Application Number	09/700,101		
INFO	ORMATION	DIS	CLOSURE	Filing Date	11/08/2000	-	
(Use as many sheets as necessary)				First Named Inventor	Gary D. Glick et al.		
				Art Unit	Not Assigned		
				Examiner Name	Not Assigned		
Sheet	1	of	1	Attorney Docket Number	UM-07268		
_							

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹						
,	1	Beurdeley-Thomas et al., Journal of Neuro-Oncology 46 (2000) 45-56					
	2	Churcher et al., Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-183					
•	3	Darrow et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132					
	4	Herranz, Medicinal Research Reviews 23 (2003) 559-603					
	5	Ramdas et al., Archieves of Biochemistry and Biophysics 368 (1999) 394-400	4				
	· 6	Ursini et al., J. Med. Chem. 43 (2000) 3596-3613					

Examiner		Date	
Signature	·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.